Table 1 Left part: description of free trough plasma concentrations (free Cmin) deduced from imatinib and AGP levels available in samples from 36 GIST patients; right part: description of the samples from seven patients with exon 9 or wt KIT identified among 20 with known tumour KIT genotype

From: Imatinib plasma levels: correlation with clinical benefit in GIST patients

 

All patients ( wt , exon 9 and exon 11 KIT)

Exon 9 and wt KIT patients

RECIST response

n (blood samples)

Median free Cmin and range (ng ml−1)

n (blood samples)

Median free Cmin and range (ng ml−1)

Progressive disease

50

13.4 (3.8–22.9)

19

10.1 (6.1–17.4)

Stable disease

63

15.8 (4.5–39.3)

4

19.9 (13.7–20.2)

Partial response

72

13.3 (2.8–33.0)

2

20.5 (14.9–26.1)

Complete response

8

26.0 (25.0–27.0)

8

26.0 (25.0–27.0)

  1. Abbreviations: AGP=α1-acid glycoprotein; GIST=gastrointestinal stromal tumour; RECIST, response evaluation criteria in solid tumours.
  2. Each patient provided between 1 and 12 samples over 3 years (median: 4 samples per patient), along with current RECIST response status.
Back to article page